{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:50:44Z","timestamp":1777431044665,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s40265-015-0412-z","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T04:43:35Z","timestamp":1433997815000},"page":"1027-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Ombitasvir\/Paritaprevir\/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection"],"prefix":"10.1007","volume":"75","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,10]]},"reference":[{"key":"412_CR1","unstructured":"Centers for Disease Control and Prevention. Infectious diseases related to travel: hepatitis C. 2014. http:\/\/wwwnc.cdc.gov. Accessed 9 Apr 2015."},{"issue":"2","key":"412_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"European Association for the Study of the Liver","year":"2014","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392\u2013420.","journal-title":"J Hepatol."},{"key":"412_CR3","unstructured":"World Health Organization. Hepatitis C: fact sheet No 164. 2014. http:\/\/www.who.int. Accessed 9 Apr 2015."},{"issue":"7265","key":"412_CR4","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798\u2013801.","journal-title":"Nature."},{"key":"412_CR5","unstructured":"AASLD and IDSA. Recommendations for testing, managing, and treating hepatitis C. 2014. http:\/\/www.hcvguidelines.org\/fullreport. Accessed 9 Apr 2015."},{"issue":"2","key":"412_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2893.2011.01527.x","volume":"19","author":"F Stickel","year":"2012","unstructured":"Stickel F, Helbling B, Heim M, et al. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. J Viral Hepat. 2012;19(2):77\u201387.","journal-title":"J Viral Hepat."},{"issue":"2","key":"412_CR7","first-page":"134","volume":"10","author":"DM Jensen","year":"2014","unstructured":"Jensen DM. Advances in combination regimens in the management of HCV infection. Gastroenterol Hepatol. 2014;10(2):134\u20136.","journal-title":"Gastroenterol Hepatol."},{"issue":"3","key":"412_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11904-014-0217-9","volume":"11","author":"K Bichoupan","year":"2014","unstructured":"Bichoupan K, Dieterich DT, Martel-Laferriere V. HIV-hepatitis C virus co-infection in the era of direct-acting antivirals. Curr HIV\/AIDS Rep. 2014;11(3):241\u20139.","journal-title":"Curr HIV\/AIDS Rep."},{"key":"412_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/liv.12745","volume":"35","author":"T Asselah","year":"2015","unstructured":"Asselah T, Marcellin P. Optimal IFN-free therapy in treatment-na\u00efve patients with HCV genotype 1 infection. Liver Int. 2015;35:56\u201364.","journal-title":"Liver Int."},{"key":"412_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025","author":"European Association for the Study of the Liver","year":"2015","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatology. doi:10.1016\/j.jhep.2015.03.025.","journal-title":"J Hepatology."},{"key":"412_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/liv.12718","volume":"35","author":"J Peter","year":"2015","unstructured":"Peter J, Nelson DR. Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients. Liver Int. 2015;35:65\u201370.","journal-title":"Liver Int."},{"key":"412_CR12","unstructured":"AbbVie Inc. VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets): US prescribing information. 2015. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/. Accessed 9 Apr 2015."},{"key":"412_CR13","unstructured":"AbbVie Limited. Viekirax 12.5\u00a0mg\/75\u00a0mg\/50\u00a0mg film-coated tablets: EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu. Accessed 8 Apr 2015."},{"key":"412_CR14","unstructured":"AbbVie Limited. Exviera 250\u00a0mg film-coated tablets: EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu. Accessed 8 Apr 2015."},{"issue":"5","key":"412_CR15","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1021\/jm401398x","volume":"57","author":"DA DeGoey","year":"2014","unstructured":"DeGoey DA, Randolph JT, Liu D, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014;57(5):2047\u201357.","journal-title":"J Med Chem."},{"issue":"2","key":"412_CR16","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1128\/AAC.04227-14","volume":"59","author":"T Pilot-Matias","year":"2015","unstructured":"Pilot-Matias T, Tripathi R, Cohen D, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59(2):988\u201397.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"412_CR17","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/AAC.04619-14","volume":"59","author":"W Kati","year":"2014","unstructured":"Kati W, Koev G, Irvin M, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2014;59(3):1505\u201311.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"412_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/AAC.04226-14","volume":"59","author":"P Krishnan","year":"2014","unstructured":"Krishnan P, Beyer J, Mistry N, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2014;59(2):979\u201387.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4 Suppl 1","key":"412_CR19","first-page":"1134A","volume":"40","author":"P Krishnan","year":"2014","unstructured":"Krishnan P. Pooled analysis of resistance in patients treated with ombitasvir\/ABT-450\/r and dasabuvir with or without ribavirin in phase 2 and phase 3 clinical trials [abstract no. 1936]. Hepatology. 2014;40(4 Suppl 1):1134A\u20135A.","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"412_CR20","doi-asserted-by":"publisher","first-page":"S220","DOI":"10.1016\/S0168-8278(15)30071-4","volume":"62","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir\/r-, ombitasvir- and dasabuvir-based regimens [abstract no. O057]. J Hepatol. 2015;62(Suppl 2):S220.","journal-title":"J Hepatol."},{"issue":"17","key":"412_CR21","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594\u2013603.","journal-title":"N Engl J Med."},{"issue":"17","key":"412_CR22","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604\u201314.","journal-title":"N Engl J Med."},{"issue":"2","key":"412_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","volume":"147","author":"P Andreone","year":"2014","unstructured":"Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359\u201365 e1.","journal-title":"Gastroenterology"},{"issue":"21","key":"412_CR24","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci P, Bernstein D, Lalezari J, et al. ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983\u201392.","journal-title":"N Engl J Med."},{"issue":"Suppl 2","key":"412_CR25","doi-asserted-by":"publisher","first-page":"S656","DOI":"10.1016\/S0168-8278(15)31049-7","volume":"62","author":"GJ Dore","year":"2015","unstructured":"Dore GJ, Knysz B, Luo Y, et al. MALACHITE-II: phase 3b trial of ombitasvir\/paritaprevir\/r and dasabuvir\u00a0+\u00a0ribavirin or telaprevir\u00a0+\u00a0peginterferon\/ribavirin in peginterferon\/ribavirin treatment-experienced adults with HCV genotype 1 [abstract no. P0847 plus poster]. J Hepatol. 2015;62(Suppl 2):S656\u20137.","journal-title":"J Hepatol."},{"issue":"Suppl 2","key":"412_CR26","doi-asserted-by":"publisher","first-page":"S653","DOI":"10.1016\/S0168-8278(15)31044-8","volume":"62","author":"B Conway","year":"2015","unstructured":"Conway B, Janczewska E, Luo Y, et al. MALACHITE-I: phase 3b trial of ombitasvir\/paritaprevir\/r and dasabuvir +\/\u2212 ribavirin or telaprevir\u00a0+\u00a0peginterferon\/ribavirin in treatment-naive adults with HCV genotype 1 [abstract no. P0842 plus poster]. J Hepatol. 2015;62(Suppl 2):S653\u20134.","journal-title":"J Hepatol."},{"key":"412_CR27","unstructured":"AbbVie. An open-label, single arm, phase 2 study to evaluate ABT-450\/r\/ABT-267 and ABT-333 with ribavirin (RBV) in adults with genotype 1 HCV infection taking methadone or buprenorphine [clinicaltrials.gov identifier NCT01911845]. 2014. http:\/\/www.clinicaltrials.gov. Accessed 9 Apr 2015."},{"issue":"4 Suppl 1","key":"412_CR28","first-page":"1132A","volume":"60","author":"DE Bernstein","year":"2014","unstructured":"Bernstein DE, Luo Y, Lalezari JP, et al. PEARL-IV trial: subgroup analysis of genotype 1a-infected patients treated with ABT-450\/r\/ombitasvir with dasabuvir with or without ribavirin [abstract no. 1933]. Hepatology. 2014;60(4 Suppl 1):1132A\u20133A.","journal-title":"Hepatology"},{"issue":"21","key":"412_CR29","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis (plus supplementary appendix). N Engl J Med. 2014;370(21):1973\u201382.","journal-title":"N Engl J Med."},{"issue":"25","key":"412_CR30","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","volume":"371","author":"PY Kwo","year":"2014","unstructured":"Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375\u201382.","journal-title":"N Engl J Med."},{"issue":"12","key":"412_CR31","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2015.1328","volume":"313","author":"MS Sulkowski","year":"2015","unstructured":"Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial (plus supplementary appendix). JAMA. 2015;313(12):1223\u201331.","journal-title":"JAMA"},{"issue":"4 Suppl","key":"412_CR32","first-page":"1159A","volume":"60","author":"DR Nelson","year":"2014","unstructured":"Nelson DR, Reddy KR, Di Bisceglie AM, et al. ABT-450\/r\/ombitasvir\u00a0+\u00a0dasabuvir with or without ribavirin in HCV genotype 1-infected patients with history of depression or bipolar disorder: pooled analysis of efficacy and safety in phase 3 trials [abstract no. 1972]. Hepatology. 2014;60(4 Suppl):1159A\u201360A.","journal-title":"Hepatology"},{"key":"412_CR33","unstructured":"Wyles D, Eron J, Trinh R, et al. High SVR regardless of time to suppression with ABT-450\/r\/ombitasvir & dasabuvir\u00a0+\u00a0RBV [abstract no. 147]. In: Conference on Retroviruses and Opportunistic Infections; 2015."},{"issue":"4 Suppl 1","key":"412_CR34","first-page":"1146A","volume":"40","author":"DE Bernstein","year":"2014","unstructured":"Bernstein DE, Marinho RT, Cohen DE, et al. Adherence to prescribed doses of ABT-450\/r\/ombitasvir, dasabuvir, and ribavirin in the phase 3 PEARL-II, PEARL-III, and PEARL-IV trials [abstract no. 1953]. Hepatology. 2014;40(4 Suppl 1):1146A.","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"412_CR35","doi-asserted-by":"publisher","first-page":"S685","DOI":"10.1016\/S0168-8278(15)31111-9","volume":"62","author":"T Hassanein","year":"2015","unstructured":"Hassanein T, Roberts S, Shafran SD, et al. Adherence to ombitasvir\/paritaprevir\/r, dasabuvir, and ribavirin is >98% in the SAPPHIRE-I and SAPPHIRE-II trials [abstract no. P0908]. J Hepatol. 2015;62(Suppl 2):S685.","journal-title":"J Hepatol."},{"issue":"Suppl 2","key":"412_CR36","doi-asserted-by":"publisher","first-page":"S668","DOI":"10.1016\/S0168-8278(15)31075-8","volume":"62","author":"Y Liu","year":"2015","unstructured":"Liu Y, Larsen L, Zeuzem S, et al. Ombitasvir\/paritaprevir\/ritonavir and dasabuvir with ribavirin (RBV) has minimal impact in health-related quality of life (HRQOL) compared with placebo during 12-week treatment in treatment-naive adults with chronic hepatitis C (CHC) [abstract no. P0873]. J Hepatol. 2015;62(Suppl 2):S668.","journal-title":"J Hepatol."},{"issue":"Suppl 2","key":"412_CR37","doi-asserted-by":"publisher","first-page":"S661","DOI":"10.1016\/S0168-8278(15)31058-8","volume":"62","author":"Y Liu","year":"2015","unstructured":"Liu Y, Larsen L, Bourliere M, et al. Ombitasvir\/paritaprevir\/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on health-related quality of life (HRQOL) compared with placebo during 12-week treatment in treatment-experienced adults with chronic hepatitis C (CHC) [abstract no. P0856]. J Hepatol. 2015;62(Suppl 2):S661.","journal-title":"J Hepatol."},{"issue":"4 Suppl 1","key":"412_CR38","first-page":"1145A","volume":"40","author":"MW Fried","year":"2014","unstructured":"Fried MW, Di Bisceglie AM, Vierling JM. Safety of ABT-450\/r\/ombitasvir\u00a0+\u00a0dasabuvir with or without ribavirin in HCV genotype 1-infected patients: results from phase 2 and phase 3 trials [abstract no. 1951]. Hepatology. 2014;40(4 Suppl 1):1145A.","journal-title":"Hepatology"},{"key":"412_CR39","unstructured":"Eron J, Wyles D, Sulkowski M, et al. TURQUOISE I: safety and efficacy of ABT-450\/r\/ombitasvir, dasabuvir and ribavirin in patients co-infected with HCV and HIV-1 [abstract no. V-673]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014."},{"issue":"4 Suppl 1","key":"412_CR40","first-page":"1157A","volume":"40","author":"S Flamm","year":"2014","unstructured":"Flamm S. Safety of ABT-450\/r\/ombitasvir\u00a0+\u00a0dasabuvir with or without ribavirin in HCV genotype 1-infected patients \u226565 years of age: results from phase 2 and 3 trials [abstract no. 1969]. Hepatology. 2014;40(4 Suppl 1):1157A\u20138A.","journal-title":"Hepatology"},{"key":"412_CR41","unstructured":"Sulkowski M, Wyles D, Slim J, et al. Hematologic analysis of ABT-450\/r\/ombitasvir and dasabuvir\u00a0+\u00a0RBV in TURQUOISE-I [abstract no. 691]. In: Conference on Retroviruses and Opportunistic Infections; 2015."},{"issue":"Suppl S1","key":"412_CR42","first-page":"1160A","volume":"60","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Forns X, Zeusem S, et al. Characteristics of HCV-infected patients with cirrhosis requiring dose reduction during treatment with direct-acting antivirals [abstract no. 1973]. Hepatology. 2014;60(Suppl S1):1160A.","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"412_CR43","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1016\/S0168-8278(15)30147-1","volume":"62","author":"PJ Pockros","year":"2015","unstructured":"Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir\/paritaprevir\/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-I study [abstract no. L01 plus oral presentation]. J Hepatol. 2015;62(Suppl 2):S257.","journal-title":"J Hepatol."},{"issue":"5","key":"412_CR44","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1517\/14656566.2014.889116","volume":"15","author":"AF Carrion","year":"2014","unstructured":"Carrion AF, Gutierrez J, Martin P. New antiviral agents for the treatment of hepatitis C: ABT-450. Expert Opin Pharmacother. 2014;15(5):711\u20136.","journal-title":"Expert Opin Pharmacother."},{"issue":"Suppl 2","key":"412_CR45","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1016\/S0168-8278(15)30101-X","volume":"62","author":"K Chayama","year":"2015","unstructured":"Chayama K, Suzuki F, Ikeda K, et al. Ombitasvir\/paritaprevir\/ritonavir for treatment of HCV genotype 1b in Japanese patients with or without cirrhosis: results from GIFT-I [abstract no. G13]. J Hepatol. 2015;62(Suppl 2):S235.","journal-title":"J Hepatol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0412-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-015-0412-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0412-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0412-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:45:32Z","timestamp":1659113132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-015-0412-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["412"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0412-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"10 June 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}